Nab-Paclitaxel Has Efficacy Equivalent to Standard Docetaxel in Previously Treated NSCLC

Noninferiority of nab-paclitaxel (Abraxane) compared with docetaxel was confirmed by assessing end points such as progression-free survival (PFS), overall survival (OS), and the objective response rate (ORR) for the treatment of previously treated patients with advanced non–small cell lung cancer (NSCLC), according to phase 3 trial results (UMIN000017487) presented virtually at the 2020 World Conference on Lung Cancer Singapore.¹

Results from a total of 503 patients were presented by Atsushi Nakamura, MD, PhD, from Sendai Kousei Hospital in Japan. Patients were randomized 1:1 to receive either nab-paclitaxel (n = 252) at 100 mg/m² on days 1, 8, and 15 every 3 weeks or docetaxel (n = 251) at 60 mg/m² on day 1 every 3 weeks. Patients were stratified by sex, histology, disease stage, ECOG performance status, number of prior chemotherapies, and previous exposure to immune checkpoint…